adagrasib
-
August 5, 2022
Adagrasib in Previously Treated Patients With KRAS G12C–Mutated Advanced NSCLC Bookmark
George Lundberg, MDAs reported by The ASCO Post, the drug adagrasib has shown some promising results in a clinical trial for people with advanced non-small cell lung cancer (NSCLC) with a KRAS-g12c mutation whose cancer progressed after prior treatment. The U.S. Food and Drug Administration (FDA) allows adagrasib to be given to people whose cancer has a KRAS-g12c mutation through expanded access.
.